NCT06503510Recruiting
Role of Interleukin-13 Pathways on Pain and Itch Sensitivity
The Role of the Interleukin-13 Pathways on Pain and Itch Sensitivity in Patients With Atopic Dermatitis and Healthy Volunteers
Source: ClinicalTrials.gov · Last updated 4 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 10 Jul 2024
- Start date
- 6 Jan 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Aalborg University
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06503510
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 6 Jan 2025 to the primary completion date, 31 Dec 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Drug addiction defined as any use of cannabis, opioids, or other drugs
- Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
- Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).
- Use of systemic and topical corticosteroids
Other
- Pregnancy or lactation
- Moles, wounds, scars, or tattoos in the area to be treated or tested
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Acute or chronic pain
- Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
- Lack of ability to cooperate
Who the study is looking for
- Healthy men and women
- 18-60 years
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aalborg University Coordinator of this site? Confirm its status | Aalborg | Denmark | Not yet recruiting |
| CNAP Coordinator of this site? Confirm its status | Gistrup | Denmark | Active, not recruiting |
| Aalborg University Coordinator of this site? Confirm its status | Gistrup | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.